Koninklijke DSM (OTCMKTS:RDSMY) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research lowered shares of Koninklijke DSM (OTCMKTS:RDSMY) from a hold rating to a strong sell rating in a research note released on Saturday, Zacks.com reports.

According to Zacks, “DSM N V ADR is involved in the Chemicals Industry. Their main focus is on base materials, performance materials, materials processing, base chemicals and fine chemicals and coating resins. They are also involved in the exploration and development of oil and natural gas deposits in the North Sea, as well as the licensing of chemical technology and know-how; in addition the company produces ingredients for bakery products. DSM is a world market leader in a number of products, including caprolactam, melamine and EPDM synthetic rubber. “

RDSMY has been the subject of several other research reports. ValuEngine lowered Koninklijke DSM from a buy rating to a hold rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. upgraded Koninklijke DSM from a neutral rating to an overweight rating in a research note on Friday, July 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $30.00.

Shares of Koninklijke DSM stock opened at $29.88 on Friday. The company has a current ratio of 2.45, a quick ratio of 1.68 and a debt-to-equity ratio of 0.29. Koninklijke DSM has a twelve month low of $19.45 and a twelve month high of $32.25. The company has a 50-day simple moving average of $31.29. The stock has a market cap of $22.50 billion, a price-to-earnings ratio of 17.27, a PEG ratio of 3.69 and a beta of 1.39.

Koninklijke DSM Company Profile

Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and materials businesses in the Netherlands, North America, the United Kingdom, France, Germany, Switzerland, the Asia-Pacific, and internationally.. The company operates through Nutrition, Materials, and Innovation Center segments.

See Also: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on Koninklijke DSM (RDSMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Jennison Associates LLC Sells 760,927 Shares of Amicus Therapeutics, Inc.
Jennison Associates LLC Sells 760,927 Shares of Amicus Therapeutics, Inc.
Jennison Associates LLC Sells 102,429 Shares of EOG Resources Inc
Jennison Associates LLC Sells 102,429 Shares of EOG Resources Inc
Jennison Associates LLC Increases Stock Holdings in BB&T Co.
Jennison Associates LLC Increases Stock Holdings in BB&T Co.
Jennison Associates LLC Sells 67,785 Shares of Performance Food Group Co
Jennison Associates LLC Sells 67,785 Shares of Performance Food Group Co
Jennison Associates LLC Boosts Stock Position in MFA FINL INC/SH
Jennison Associates LLC Boosts Stock Position in MFA FINL INC/SH
Jennison Associates LLC Lowers Stock Holdings in Mcdonald’s Corp
Jennison Associates LLC Lowers Stock Holdings in Mcdonald’s Corp


© 2006-2019 Ticker Report